Met as a therapeutic target in HCC: Facts and hopes

Journal of Hepatology

Volumn 60, Issue 2, 2014, Pages 442-452

  Giordano, Silvia ^a   Columbano, Amedeo ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Clinical trials; Hepatocellular carcinoma; HGF; MET; Targeted therapies

Indexed keywords

SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SORAFENIB; TYROSINE KINASE RECEPTOR;

ADVANCED CANCER; ANTIANGIOGENIC THERAPY; CANCER GROWTH; GENE OVEREXPRESSION; HUMAN; LIVER; LIVER CELL CARCINOMA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC THERAPY;

CLINICAL TRIALS; HEPATOCELLULAR CARCINOMA; HGF; MET; TARGETED THERAPIES;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; HEPATOCYTE GROWTH FACTOR; HUMANS; LIVER NEOPLASMS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION;

EID: 84892549017     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.09.009     Document Type: Review

References (89)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. J.M. Llovet, A.M. Di Bisceglie, J. Bruix, B.S. Kramer, R. Lencioni, and A.X. Zhu et al. Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 2008 698 711
3. J.M. Llovet, and J. Bruix Molecular targeted therapies in hepatocellular carcinoma Hepatology 48 2008 1312 1327
4. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc et al. Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
5. J. Luo, N.L. Solimini, and S.J. Elledge Principles of cancer therapy: oncogene and non-oncogene addiction Cell 136 2009 823 837
6. S. Giordano, C. Ponzetto, M.F. Di Renzo, C.S. Cooper, and P.M. Comoglio Tyrosine kinase receptor indistinguishable from the c-met protein Nature 339 1989 155 156
7. S. Corso, and S. Giordano Cell autonomous and non-cell autonomous mechanisms of HGF/MET-driven resistance to targeted therapies: from basic research to a clinical perspective Cancer Discov 3 2013 978 992
8. D.P. Bottaro, J.S. Rubin, D.L. Faletto, A.M. Chan, T.E. Kmiecik, and G.F. Vande Woude et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product Science 251 1991 802 804
9. L. Naldini, E. Vigna, R.P. Narsimhan, G. Gaudino, R. Zarnegar, and G.K. Michalopoulos et al. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET Oncogene 6 1991 501 504
10. C. Birchmeier, W. Birchmeier, E. Gherardi, and G.F. Vande Woude Met, metastasis, motility and more Nat Rev Mol Cell Biol 4 2003 915 925
11. C. Migliore, and S. Giordano Molecular cancer therapy: can our expectation be MET? Eur J Cancer 44 2008 641 651
12. R. van der Voort, T.E. Taher, V.J. Wielenga, M. Spaargaren, R. Prevo, and L. Smit et al. Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met J Biol Chem 274 1999 6499 6506
13. V. Orian-Rousseau, L. Chen, J.P. Sleeman, P. Herrlich, and H. Ponta CD44 is required for two consecutive steps in HGF/c-Met signaling Genes Dev 16 2002 3074 3086
14. L. Trusolino, A. Bertotti, and P.M. Comoglio A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth Cell 107 2001 643 654
15. S. Giordano, S. Corso, P. Conrotto, S. Artigiani, G. Gilestro, and D. Barberis et al. The semaphorin 4D receptor controls invasive growth by coupling with Met Nat Cell Biol 4 2002 720 724
16. M. Jo, D.B. Stolz, J.E. Esplen, K. Dorko, G.K. Michalopoulos, and S.C. Strom Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells J Biol Chem 275 2000 8806 8811
17. J.D. Bergstrom, B. Westermark, and N.E. Heldin Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells Exp Cell Res 259 2000 293 299
18. O.M. Fischer, S. Giordano, P.M. Comoglio, and A. Ullrich Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells J Biol Chem 279 2004 28970 28978
19. K.V. Lu, J.P. Chang, C.A. Parachoniak, M.M. Pandika, M.K. Aghi, and D. Meyronet et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex Cancer Cell 22 2012 21 35
20. X. Wang, M.C. DeFrances, Y. Dai, P. Pediaditakis, C. Johnson, and A. Bell et al. A mechanism of cell survival: sequestration of Fas by the HGF receptor Met Mol Cell 9 2002 411 421
21. H. Sakata, H. Takayama, R. Sharp, J.S. Rubin, G. Merlino, and W.J. Larochelle Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers Cell Growth Differ 7 1996 1513 1523
22. R. Wang, L.D. Ferrell, S. Faouzi, J.J. Maher, and J.M. Bishop Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice J Cell Biol 153 2001 1023 1034
23. H. Takayama, W.J. Larochelle, R. Sharp, T. Otsuka, P. Kriebel, and M. Anver et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor Proc Natl Acad Sci U S A 94 1997 701 706
24. T.J. Liang, A.E. Reid, R. Xavier, R.D. Cardiff, and T.C. Wang Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors J Clin Invest 97 1996 2872 2877
25. P.M. Comoglio, S. Giordano, and L. Trusolino Drug development of MET inhibitors: targeting oncogene addiction and expedience Nat Rev Drug Discov 7 2008 504 516
26. L. Schmidt, F.M. Duh, F. Chen, T. Kishida, G. Glenn, and P. Choyke et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas Nat Genet 16 1997 68 73
27. P. Michieli, C. Basilico, S. Pennacchietti, A. Maffe, L. Tamagnone, and S. Giordano et al. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists Oncogene 18 1999 5221 5231
28. T. Nakamura, K. Nawa, and A. Ichihara Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats Biochem Biophys Res Commun 122 1984 1450 1459
29. T. Nakamura, T. Nishizawa, M. Hagiya, T. Seki, M. Shimonishi, and A. Sugimura et al. Molecular cloning and expression of human hepatocyte growth factor Nature 342 1989 440 443
30. R.A. Furlong, T. Takehara, W.G. Taylor, T. Nakamura, and J.S. Rubin Comparison of biological and immunochemical properties indicates that scatter factor and hepatocyte growth factor are indistinguishable J Cell Sci 100 1991 173 177
31. N. Shima, M. Nagao, F. Ogaki, E. Tsuda, A. Murakami, and K. Higashio Tumor cytotoxic factor/hepatocyte growth factor from human fibroblasts: cloning of its cDNA, purification and characterization of recombinant protein Biochem Biophys Res Commun 180 1991 1151 1158
32. K. Kosai, K. Matsumoto, S. Nagata, Y. Tsujimoto, and T. Nakamura Abrogation of Fas-induced fulminant hepatic failure in mice by hepatocyte growth factor Biochem Biophys Res Commun 244 1998 683 690
33. L. Amicone, F.M. Spagnoli, G. Spath, S. Giordano, C. Tommasini, and S. Bernardini et al. Transgenic expression in the liver of truncated Met blocks apoptosis and permits immortalization of hepatocytes EMBO J 16 1997 495 503
34. L. Wang, X. Wang, G. Xie, L. Wang, and C.K. Hill DeLeve LD Liver sinusoidal endothelial cell progenitor cells promote liver regeneration in rats J Clin Invest 122 2012 1567 1573
35. C.G. Huh, V.M. Factor, A. Sanchez, K. Uchida, E.A. Conner, and S.S. Thorgeirsson Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair Proc Natl Acad Sci U S A 101 2004 4477 4482
36. M. Borowiak, A.N. Garratt, T. Wustefeld, M. Strehle, C. Trautwein, and C. Birchmeier Met provides essential signals for liver regeneration Proc Natl Acad Sci U S A 101 2004 10608 10613
37. A. Giebeler, M.V. Boekschoten, C. Klein, M. Borowiak, C. Birchmeier, and N. Gassler et al. C-Met confers protection against chronic liver tissue damage and fibrosis progression after bile duct ligation in mice Gastroenterology 137 2009 308
38. F. Aberger, G. Schmidt, and K. Richter The Xenopus homologue of hepatocyte growth factor-like protein is specifically expressed in the presumptive neural plate during gastrulation Mech Dev 54 1996 23 37
39. S. Takeo, H. Arai, N. Kusano, T. Harada, T. Furuya, and S. Kawauchi et al. Examination of oncogene amplification by genomic DNA microarray in hepatocellular carcinomas: comparison with comparative genomic hybridization analysis Cancer Genet Cytogenet 130 2001 127 132
40. S. Kondo, H. Ojima, H. Tsuda, J. Hashimoto, C. Morizane, and M. Ikeda et al. Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma Int J Clin Oncol 18 2013 207 213
41. K. Wang, H.Y. Lim, S. Shi, J. Lee, S. Deng, and T. Xie et al. Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma Hepatology 58 2013 706 717
42. C. Guichard, G. Amaddeo, S. Imbeaud, Y. Ladeiro, L. Pelletier, and I.B. Maad et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma Nat Genet 44 2012 694 698
43. C.C. Jia, T.T. Wang, W. Liu, B.S. Fu, X. Hua, and G.Y. Wang et al. Cancer-associated fibroblasts from hepatocellular carcinoma promote malignant cell proliferation by HGF secretion PLoS One 8 2013 e63243
44. T. Ueki, J. Fujimoto, T. Suzuki, H. Yamamoto, and E. Okamoto Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma Hepatology 25 1997 862 866
45. L. Boix, J.L. Rosa, F. Ventura, A. Castells, J. Bruix, and J. Rodes et al. C-met mRNA overexpression in human hepatocellular carcinoma Hepatology 19 1994 88 91
46. K. Suzuki, N. Hayashi, Y. Yamada, H. Yoshihara, Y. Miyamoto, and Y. Ito et al. Expression of the c-met protooncogene in human hepatocellular carcinoma Hepatology 20 1994 1231 1236
47. O. Noguchi, N. Enomoto, T. Ikeda, F. Kobayashi, F. Marumo, and C. Sato Gene expressions of c-met and hepatocyte growth factor in chronic liver disease and hepatocellular carcinoma J Hepatol 24 1996 286 292
48. A. Kiss, N.J. Wang, J.P. Xie, and S.S. Thorgeirsson Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met, TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas Clin Cancer Res 3 1997 1059 1066
49. D. Tavian, P.G. De, A. Benetti, N. Portolani, S.M. Giulini, and S. Barlati U-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma Int J Cancer 87 2000 644 649
50. M. Daveau, M. Scotte, A. Francois, C. Coulouarn, G. Ros, and Y. Tallet et al. Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma Mol Carcinog 36 2003 130 141
51. M. Suzuki, H. Shiraha, T. Fujikawa, N. Takaoka, N. Ueda, and Y. Nakanishi et al. Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma J Biol Chem 280 2005 6409 6415
52. J. Gao, X. Feng, Y. Inagaki, P. Song, N. Kokudo, and K. Hasegawa et al. Des-gamma-carboxy prothrombin and c-Met were concurrently and extensively expressed in hepatocellular carcinoma and associated with tumor recurrence Biosci Trends 6 2012 153 159
53. I.C. Weitz, and H.A. Liebman Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review Hepatology 18 1993 990 997
54. P. Kaposi-Novak, J.S. Lee, L. Gomez-Quiroz, C. Coulouarn, V.M. Factor, and S.S. Thorgeirsson Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype J Clin Invest 116 2006 1582 1595
55. G. Shiota, D.B. Rhoads, T.C. Wang, T. Nakamura, and E.V. Schmidt Hepatocyte growth factor inhibits growth of hepatocellular carcinoma cells Proc Natl Acad Sci U S A 89 1992 373 377
56. H. Ogasawara, J. Hiramoto, M. Takahashi, K. Shirahama, A. Furusaka, and S. Hiyane et al. Hepatocyte growth factor stimulates DNA synthesis in rat preneoplastic hepatocytes but not in liver carcinoma cells Gastroenterology 114 1998 775 781
57. K. Nakanishi, J. Fujimoto, T. Ueki, K. Kishimoto, T. Hashimoto-Tamaoki, and J. Furuyama et al. Hepatocyte growth factor promotes migration of human hepatocellular carcinoma via phosphatidylinositol 3-kinase Clin Exp Metastasis 17 1999 507 514
58. E. Shirako, N. Hirayama, Y. Tsukada, T. Tanaka, and N. Kitamura Up-regulation of p21CIP1 expression mediated by ERK-dependent and -independent pathways contributes to hepatocyte growth factor-induced inhibition of HepG2 hepatoma cell proliferation J Cell Biochem 104 2008 176 188
59. S.Z. Zhang, F.Y. Pan, J.F. Xu, J. Yuan, S.Y. Guo, and G. Dai et al. Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo Mol Cancer Ther 4 2005 1577 1584
60. A. Salvi, B. Arici, N. Portolani, S.M. Giulini, P.G. De, and S. Barlati In vitro c-met inhibition by antisense RNA and plasmid-based RNAi down-modulates migration and invasion of hepatocellular carcinoma cells Int J Oncol 31 2007 451 460
61. B. Xie, R. Xing, P. Chen, Y. Gou, S. Li, and J. Xiao et al. Down-regulation of c-Met expression inhibits human HCC cells growth and invasion by RNA interference J Surg Res 162 2010 231 238
62. C. Schmidt, F. Bladt, S. Goedecke, V. Brinkmann, W. Zschiesche, and M. Sharpe et al. Scatter factor/hepatocyte growth factor is essential for liver development Nature 373 1995 699 702
63. Y. Uehara, O. Minowa, C. Mori, K. Shiota, J. Kuno, and T. Noda et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor Nature 373 1995 702 705
64. T. Takami, P. Kaposi-Novak, K. Uchida, L.E. Gomez-Quiroz, E.A. Conner, and V.M. Factor et al. Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis Cancer Res 67 2007 9844 9851
65. P. Marx-Stoelting, M. Borowiak, T. Knorpp, C. Birchmeier, A. Buchmann, and M. Schwarz Hepatocarcinogenesis in mice with a conditional knockout of the hepatocyte growth factor receptor c-Met Int J Cancer 124 2009 1767 1772
66. A.D. Tward, K.D. Jones, S. Yant, M.A. Kay, R. Wang, and J.M. Bishop Genomic progression in mouse models for liver tumors Cold Spring Harb Symp Quant Biol 70 2005 217 224
67. M.L. Liu, W.M. Mars, and G.K. Michalopoulos Hepatocyte growth factor inhibits cell proliferation in vivo of rat hepatocellular carcinomas induced by diethylnitrosamine Carcinogenesis 16 1995 841 843
68. M. Yaono, R. Hasegawa, Y. Mizoguchi, M. Futakuchi, T. Nakamura, and N. Ito et al. Hepatocyte growth factor enhancement of preneoplastic hepatic foci development in rats treated with diethylnitrosamine and N-ethyl-N- hydroxyethylnitrosamine Jpn J Cancer Res 86 1995 718 723
69. G. Shiota, T.C. Wang, T. Nakamura, and E.V. Schmidt Hepatocyte growth factor in transgenic mice: effects on hepatocyte growth, liver regeneration and gene expression Hepatology 19 1994 962 972
70. N. Horiguchi, H. Takayama, M. Toyoda, T. Otsuka, T. Fukusato, and G. Merlino et al. Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine Oncogene 21 2002 1791 1799
71. E. Santoni-Rugiu, K.H. Preisegger, A. Kiss, T. Audolfsson, G. Shiota, and E.V. Schmidt et al. Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model Proc Natl Acad Sci U S A 93 1996 9577 9582
72. G. Shiota, H. Kawasaki, T. Nakamura, and E.V. Schmidt Characterization of double transgenic mice expressing hepatocye growth factor and transforming growth factor alpha Res Commun Mol Pathol Pharmacol 90 1995 17 24
73. F. Bussolino, M.F. Di Renzo, M. Ziche, E. Bocchietto, M. Olivero, and L. Naldini et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth J Cell Biol 119 1992 629 641
74. Y.W. Zhang, Y. Su, O.V. Volpert, and G.F. Vande Woude Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation Proc Natl Acad Sci U S A 100 2003 12718 12723
75. C. Eckerich, S. Zapf, R. Fillbrandt, S. Loges, M. Westphal, and K. Lamszus Hypoxia can induce c-Met expression in glioma cells and enhance SF/HGF-induced cell migration Int J Cancer 121 2007 276 283
76. S. Pennacchietti, P. Michieli, M. Galluzzo, M. Mazzone, S. Giordano, and P.M. Comoglio Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene Cancer Cell 3 2003 347 361
77. S.D. Rose, and M.K. Aghi Mechanisms of evasion to antiangiogenic therapy in glioblastoma Clin Neurosurg 57 2010 123 128
78. H. Huynh, R. Ong, and K.C. Soo Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma Angiogenesis 15 2012 59 70
79. R.E. Martell, I. Puzanov, W.W. Ma, A. Santoro, G.K. Dy, and L.W. Goff et al. Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study (abstract) J Clin Oncol 30 2012 abstr 4117
80. N. Munshi, S. Jeay, Y. Li, C.R. Chen, D.S. France, and M.A. Ashwell et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity Mol Cancer Ther 9 2010 1544 1553
81. A. Santoro, L. Rimassa, I. Borbath, B. Daniele, S. Salvagni, and J.L. Van Laethem et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study Lancet Oncol 14 2013 55 63
82. R. Katayama, A. Aoyama, T. Yamori, J. Qi, T. Oh-Hara, and Y. Song et al. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition Cancer Res 73 2013 3087 3096
83. C. Basilico, S. Pennacchietti, E. Vigna, C. Chiriaco, S. Arena, and A. Bardelli et al. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET Clin Cancer Res 19 2013 2381 2392
84. J. O'Shaughnessy, C. Osborne, J.E. Pippen, M. Yoffe, D. Patt, and C. Rocha et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer N Engl J Med 364 2011 205 214
85. X. Liu, Y. Shi, D.X. Maag, J.P. Palma, M.J. Patterson, and P.A. Ellis et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor Clin Cancer Res 18 2012 510 523
86. A.G. Patel, S.B. De Lorenzo, K.S. Flatten, G.G. Poirier, and S.H. Kaufmann Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro Clin Cancer Res 18 2012 1655 1662
87. T. Yau, W. Sukeepaisarnjaroen, Y. Chao, C. Yen, W. Lausoontornsiri, and P. Chen et al. A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC) J Clin Oncol 30 2012 4108
88. C. Verslype, A.L. Cohn, R.K. Kelley, T. Yang, W. Su, and D.A. Ramies et al. Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT) J Clin Oncol 30 2012 4007
89. C. Selden, S. Farnaud, S.F. Ding, N. Habib, C. Foster, and H.J. Hodgson Expression of hepatocyte growth factor mRNA, and c-met mRNA (hepatocyte growth factor receptor) in human liver tumours J Hepatol 21 1994 227 234